Goette Andreas, Cantu Francesco, van Erven Lieselot, Geelen Peter, Halimi Franck, Merino Jose L, Morgan John M
Division of Cardiology, University Hospital Magdeburg, Magdeburg, Germany.
Europace. 2009 Jan;11(1):31-4. doi: 10.1093/europace/eun301. Epub 2008 Nov 11.
Although the use of implantable cardioverter defibrillator (ICD) therapy has increased over the last decades, the reporting of ICD lead performance is inadequate. So far, there is neither a European nor worldwide registry on ICD leads. The published long-term results from national or multicentre registries encompass relatively small patient cohorts. Nevertheless, the failure of ICD leads may have substantial clinical consequences, including failure to sense, failure to pace, failure to defibrillate, inappropriate shocks, and even death of the patient. The reported ICD lead survival varies significantly between studies: 91-99% at 2 years, 85-95% at 5 years, and 60-72% at 8 years. Thus, the true incidence of lead malfunction cannot be defined as outlined in the present review. One current initiative of the European Heart Rhythm Association is to initiate and develop a Europe-wide registry to monitor, over a prolonged follow-up period, the performance of ICDs and ICD leads.
尽管在过去几十年里植入式心脏复律除颤器（ICD）治疗的使用有所增加，但ICD导线性能的报告并不充分。到目前为止，欧洲和全球都没有关于ICD导线的登记系统。国家或多中心登记系统公布的长期结果所涵盖的患者队列相对较小。然而，ICD导线故障可能会产生重大的临床后果，包括感知失败、起搏失败、除颤失败、不适当电击，甚至患者死亡。不同研究报告的ICD导线生存率差异显著：2年时为91%-99%，5年时为85%-95%，8年时为60%-72%。因此，正如本综述所述，导线故障的真实发生率尚无法确定。欧洲心律协会目前的一项举措是启动并建立一个全欧洲范围的登记系统，在延长的随访期内监测ICD及ICD导线的性能。
